Key clinical point: The overall incidence of synchronous bilateral breast cancer (BBC) and metachronous BBC (MBBC) in patients with a history of lobular carcinoma in situ (LCIS) was 2%, with the risk for MBBC being even lower in women with hormone receptor-positive BC and those receiving endocrine therapy (ET).

Major finding: The estimated 5-year risk of developing MBBC was 6.4% (95% CI 1.9%-10.7%) among women with a remaining contralateral breast at risk, with the risk being lower among those with estrogen (hazard ratio [HR] 0.13; P = .015) or progesterone (HR 0.24; P = .047) receptor-positive BC and those who received ET (HR 0.17; P = .005).

Study details: This study included 1651 women with a history of LCIS, of which 249 women developed unilateral or bilateral BC during a median follow-up of 7 years.

Disclosures: This study was partly supported by the US National Institutes of Health/National Cancer Institute Cancer Center. TA King declared receiving speakers' honoraria and serving on advisory boards for several sources. The other authors declared no conflicts of interest.

Source: Mallory MA et al. Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. Breast Cancer Res Treat. 2022 (Apr 29). Doi: 10.1007/s10549-022-06532-4 

Key clinical point: The overall incidence of synchronous bilateral breast cancer (BBC) and metachronous BBC (MBBC) in patients with a history of lobular carcinoma in situ (LCIS) was 2%, with the risk for MBBC being even lower in women with hormone receptor-positive BC and those receiving endocrine therapy (ET).

Major finding: The estimated 5-year risk of developing MBBC was 6.4% (95% CI 1.9%-10.7%) among women with a remaining contralateral breast at risk, with the risk being lower among those with estrogen (hazard ratio [HR] 0.13; P = .015) or progesterone (HR 0.24; P = .047) receptor-positive BC and those who received ET (HR 0.17; P = .005).

Study details: This study included 1651 women with a history of LCIS, of which 249 women developed unilateral or bilateral BC during a median follow-up of 7 years.

Disclosures: This study was partly supported by the US National Institutes of Health/National Cancer Institute Cancer Center. TA King declared receiving speakers' honoraria and serving on advisory boards for several sources. The other authors declared no conflicts of interest.

Source: Mallory MA et al. Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. Breast Cancer Res Treat. 2022 (Apr 29). Doi: 10.1007/s10549-022-06532-4 

Key clinical point: The overall incidence of synchronous bilateral breast cancer (BBC) and metachronous BBC (MBBC) in patients with a history of lobular carcinoma in situ (LCIS) was 2%, with the risk for MBBC being even lower in women with hormone receptor-positive BC and those receiving endocrine therapy (ET).

Major finding: The estimated 5-year risk of developing MBBC was 6.4% (95% CI 1.9%-10.7%) among women with a remaining contralateral breast at risk, with the risk being lower among those with estrogen (hazard ratio [HR] 0.13; P = .015) or progesterone (HR 0.24; P = .047) receptor-positive BC and those who received ET (HR 0.17; P = .005).

Study details: This study included 1651 women with a history of LCIS, of which 249 women developed unilateral or bilateral BC during a median follow-up of 7 years.

Disclosures: This study was partly supported by the US National Institutes of Health/National Cancer Institute Cancer Center. TA King declared receiving speakers' honoraria and serving on advisory boards for several sources. The other authors declared no conflicts of interest.

Source: Mallory MA et al. Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. Breast Cancer Res Treat. 2022 (Apr 29). Doi: 10.1007/s10549-022-06532-4 

Key clinical point: The combination of ibandronate and endocrine therapy (ET) failed to improve disease-free survival (DFS) compared with ET alone in postmenopausal women with estrogen receptor-positive (ER+) early breast cancer (BC).

Major finding: During a median follow-up of 8.5 years, DFS was not significantly different between the ibandronate+ET and ET treatment arms (hazard ratio [HR] 0.97; log-rank P = .811). Overall, the incidence of adverse events, particularly osteonecrosis (P = .002) and dyspepsia (P < .001), was higher in the ibandronate+ET vs. ET treatment arm.

Study details: This phase 3, TEAM-IIB trial included 1116 postmenopausal women with invasive stage I-III ER+ BC who were randomly assigned to receive ET for 5 years with or without 50 mg adjuvant oral ibandronate once daily for 3 years.

Disclosures: This study was supported by grants from Roche Nederland B.V. and Pfizer Nederland B.V. Some authors declared serving as consultants, advisors, or receiving research funding, honoraria, travel support, or accommodation expenses from several sources, including Roche and Pfizer.

Source: Vliek SB, Noordhoek I, et al. Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer (BOOG 2006-04): Randomized phase III TEAM-IIB trial. J Clin Oncol. 2022 Apr 20. doi: 10.1200/JCO.21.00311.

Key clinical point: The combination of ibandronate and endocrine therapy (ET) failed to improve disease-free survival (DFS) compared with ET alone in postmenopausal women with estrogen receptor-positive (ER+) early breast cancer (BC).

Major finding: During a median follow-up of 8.5 years, DFS was not significantly different between the ibandronate+ET and ET treatment arms (hazard ratio [HR] 0.97; log-rank P = .811). Overall, the incidence of adverse events, particularly osteonecrosis (P = .002) and dyspepsia (P < .001), was higher in the ibandronate+ET vs. ET treatment arm.

Study details: This phase 3, TEAM-IIB trial included 1116 postmenopausal women with invasive stage I-III ER+ BC who were randomly assigned to receive ET for 5 years with or without 50 mg adjuvant oral ibandronate once daily for 3 years.

Disclosures: This study was supported by grants from Roche Nederland B.V. and Pfizer Nederland B.V. Some authors declared serving as consultants, advisors, or receiving research funding, honoraria, travel support, or accommodation expenses from several sources, including Roche and Pfizer.

Source: Vliek SB, Noordhoek I, et al. Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer (BOOG 2006-04): Randomized phase III TEAM-IIB trial. J Clin Oncol. 2022 Apr 20. doi: 10.1200/JCO.21.00311.

Key clinical point: The combination of ibandronate and endocrine therapy (ET) failed to improve disease-free survival (DFS) compared with ET alone in postmenopausal women with estrogen receptor-positive (ER+) early breast cancer (BC).

Major finding: During a median follow-up of 8.5 years, DFS was not significantly different between the ibandronate+ET and ET treatment arms (hazard ratio [HR] 0.97; log-rank P = .811). Overall, the incidence of adverse events, particularly osteonecrosis (P = .002) and dyspepsia (P < .001), was higher in the ibandronate+ET vs. ET treatment arm.

Study details: This phase 3, TEAM-IIB trial included 1116 postmenopausal women with invasive stage I-III ER+ BC who were randomly assigned to receive ET for 5 years with or without 50 mg adjuvant oral ibandronate once daily for 3 years.

Disclosures: This study was supported by grants from Roche Nederland B.V. and Pfizer Nederland B.V. Some authors declared serving as consultants, advisors, or receiving research funding, honoraria, travel support, or accommodation expenses from several sources, including Roche and Pfizer.

Source: Vliek SB, Noordhoek I, et al. Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer (BOOG 2006-04): Randomized phase III TEAM-IIB trial. J Clin Oncol. 2022 Apr 20. doi: 10.1200/JCO.21.00311.

Key clinical point: Palbociclib plus endocrine therapy (ET) demonstrated no survival benefit over capecitabine in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (BC) who progressed on prior aromatase inhibitor (AI) therapy.

Major finding: The median overall survival was not significantly different between the palbociclib+ET and capecitabine groups in the overall population (adjusted hazard ratio [aHR] 1.00; P = .995) and the wild-type estrogen receptor-1 population (aHR 1.06; P = .683). No new safety signals were identified.

Study details: Findings are from the phase 3 PEARL study including 601 postmenopausal women with HR+/HER2− metastatic BC who progressed on prior AI therapy and were randomly assigned to receive capecitabine or palbociclib+ET with exemestane or fulvestrant.

Disclosures: This study was supported by Pfizer Inc. and AstraZeneca. Two authors declared being employees and having stock options in Pfizer, and the other authors reported ties with several sources, including Pfizer and AstraZeneca.

Source: Martin M et al. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022;168:12-24 (Apr 14). Doi: 10.1016/j.ejca.2022.03.006

Key clinical point: Palbociclib plus endocrine therapy (ET) demonstrated no survival benefit over capecitabine in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (BC) who progressed on prior aromatase inhibitor (AI) therapy.

Major finding: The median overall survival was not significantly different between the palbociclib+ET and capecitabine groups in the overall population (adjusted hazard ratio [aHR] 1.00; P = .995) and the wild-type estrogen receptor-1 population (aHR 1.06; P = .683). No new safety signals were identified.

Study details: Findings are from the phase 3 PEARL study including 601 postmenopausal women with HR+/HER2− metastatic BC who progressed on prior AI therapy and were randomly assigned to receive capecitabine or palbociclib+ET with exemestane or fulvestrant.

Disclosures: This study was supported by Pfizer Inc. and AstraZeneca. Two authors declared being employees and having stock options in Pfizer, and the other authors reported ties with several sources, including Pfizer and AstraZeneca.

Source: Martin M et al. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022;168:12-24 (Apr 14). Doi: 10.1016/j.ejca.2022.03.006

Key clinical point: Palbociclib plus endocrine therapy (ET) demonstrated no survival benefit over capecitabine in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (BC) who progressed on prior aromatase inhibitor (AI) therapy.

Major finding: The median overall survival was not significantly different between the palbociclib+ET and capecitabine groups in the overall population (adjusted hazard ratio [aHR] 1.00; P = .995) and the wild-type estrogen receptor-1 population (aHR 1.06; P = .683). No new safety signals were identified.

Study details: Findings are from the phase 3 PEARL study including 601 postmenopausal women with HR+/HER2− metastatic BC who progressed on prior AI therapy and were randomly assigned to receive capecitabine or palbociclib+ET with exemestane or fulvestrant.

Disclosures: This study was supported by Pfizer Inc. and AstraZeneca. Two authors declared being employees and having stock options in Pfizer, and the other authors reported ties with several sources, including Pfizer and AstraZeneca.

Source: Martin M et al. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022;168:12-24 (Apr 14). Doi: 10.1016/j.ejca.2022.03.006

Key clinical point: Neoadjuvant chemotherapy with paclitaxel can be safely omitted in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor-negative (HR−) early breast cancer (BC) who achieved pathological complete response (pCR) with only trastuzumab+pertuzumab.

Major finding: The 5-year invasive disease-free survival (iDFS; hazard ratio [HR] 0.32; P = .15) and overall survival (HR 0.41; P = .43) were achieved by a similar proportion early responders in the trastuzumab+pertuzumab without paclitaxel group and all patients in the trastuzumab+pertuzumab+paclitaxel group, irrespective of an early response, with the achievement of pCR being associated with improvement in iDFS (HR 0.14; P = .011).

Study details: Findings are from the phase 2, WSG-ADAPT-HER2+/HR− trial including 134 women with HER2+/HR− early BC who were randomly assigned to receive trastuzumab+pertuzumab with or without weekly paclitaxel for 12 weeks.

Disclosures: This study was funded by Roche and Bayer. Some authors declared serving as codirectors at the West German Study Group or on data safety monitoring boards or advisory boards or receiving research funding, consulting fees, honoraria, or travel support from several sources.

Source: Nitz U et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): Survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):625-635 (Apr 8). Doi: 10.1016/S1470-2045(22)00159-0

Key clinical point: Neoadjuvant chemotherapy with paclitaxel can be safely omitted in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor-negative (HR−) early breast cancer (BC) who achieved pathological complete response (pCR) with only trastuzumab+pertuzumab.

Major finding: The 5-year invasive disease-free survival (iDFS; hazard ratio [HR] 0.32; P = .15) and overall survival (HR 0.41; P = .43) were achieved by a similar proportion early responders in the trastuzumab+pertuzumab without paclitaxel group and all patients in the trastuzumab+pertuzumab+paclitaxel group, irrespective of an early response, with the achievement of pCR being associated with improvement in iDFS (HR 0.14; P = .011).

Study details: Findings are from the phase 2, WSG-ADAPT-HER2+/HR− trial including 134 women with HER2+/HR− early BC who were randomly assigned to receive trastuzumab+pertuzumab with or without weekly paclitaxel for 12 weeks.

Disclosures: This study was funded by Roche and Bayer. Some authors declared serving as codirectors at the West German Study Group or on data safety monitoring boards or advisory boards or receiving research funding, consulting fees, honoraria, or travel support from several sources.

Source: Nitz U et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): Survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):625-635 (Apr 8). Doi: 10.1016/S1470-2045(22)00159-0

Key clinical point: Neoadjuvant chemotherapy with paclitaxel can be safely omitted in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor-negative (HR−) early breast cancer (BC) who achieved pathological complete response (pCR) with only trastuzumab+pertuzumab.

Major finding: The 5-year invasive disease-free survival (iDFS; hazard ratio [HR] 0.32; P = .15) and overall survival (HR 0.41; P = .43) were achieved by a similar proportion early responders in the trastuzumab+pertuzumab without paclitaxel group and all patients in the trastuzumab+pertuzumab+paclitaxel group, irrespective of an early response, with the achievement of pCR being associated with improvement in iDFS (HR 0.14; P = .011).

Study details: Findings are from the phase 2, WSG-ADAPT-HER2+/HR− trial including 134 women with HER2+/HR− early BC who were randomly assigned to receive trastuzumab+pertuzumab with or without weekly paclitaxel for 12 weeks.

Disclosures: This study was funded by Roche and Bayer. Some authors declared serving as codirectors at the West German Study Group or on data safety monitoring boards or advisory boards or receiving research funding, consulting fees, honoraria, or travel support from several sources.

Source: Nitz U et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): Survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):625-635 (Apr 8). Doi: 10.1016/S1470-2045(22)00159-0

Key clinical point: Digital breast tomosynthesis plus synthesized 2-dimensional (s2D) mammography was superior to standard digital mammography for the detection of invasive breast cancer (BC).

Major finding: Detection rate of all invasive BC (odds ratio 1.48; P < .0001) was higher with digital breast tomosynthesis+s2D mammography vs digital mammography. None of the adverse events were classified as serious or related to the device used.

Study details: Findings are from the open-label, superiority TOSYMA trial including 99,689 women who were randomly assigned to undergo BC screening with digital breast tomosynthesis+s2D mammography or digital mammography.

Disclosures: This study was funded by Deutsche Forschungsgemeinschaft. Some authors declared running a third-party funded project at the University of Münster or receiving grants, honoraria, or payments from several sources.

Source: Heindel W et al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): A multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol. 2022;23(5):601-611 (Apr 12). Doi: 10.1016/S1470-2045(22)00194-2

Key clinical point: Digital breast tomosynthesis plus synthesized 2-dimensional (s2D) mammography was superior to standard digital mammography for the detection of invasive breast cancer (BC).

Major finding: Detection rate of all invasive BC (odds ratio 1.48; P < .0001) was higher with digital breast tomosynthesis+s2D mammography vs digital mammography. None of the adverse events were classified as serious or related to the device used.

Study details: Findings are from the open-label, superiority TOSYMA trial including 99,689 women who were randomly assigned to undergo BC screening with digital breast tomosynthesis+s2D mammography or digital mammography.

Disclosures: This study was funded by Deutsche Forschungsgemeinschaft. Some authors declared running a third-party funded project at the University of Münster or receiving grants, honoraria, or payments from several sources.

Source: Heindel W et al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): A multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol. 2022;23(5):601-611 (Apr 12). Doi: 10.1016/S1470-2045(22)00194-2

Key clinical point: Digital breast tomosynthesis plus synthesized 2-dimensional (s2D) mammography was superior to standard digital mammography for the detection of invasive breast cancer (BC).

Major finding: Detection rate of all invasive BC (odds ratio 1.48; P < .0001) was higher with digital breast tomosynthesis+s2D mammography vs digital mammography. None of the adverse events were classified as serious or related to the device used.

Study details: Findings are from the open-label, superiority TOSYMA trial including 99,689 women who were randomly assigned to undergo BC screening with digital breast tomosynthesis+s2D mammography or digital mammography.

Disclosures: This study was funded by Deutsche Forschungsgemeinschaft. Some authors declared running a third-party funded project at the University of Münster or receiving grants, honoraria, or payments from several sources.

Source: Heindel W et al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): A multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol. 2022;23(5):601-611 (Apr 12). Doi: 10.1016/S1470-2045(22)00194-2

Key clinical point: Switch to maintenance endocrine therapy (ET)+bevacizumab with an option of reinduction may be a better alternative to continuing weekly paclitaxel+bevacizumab in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced/metastatic breast cancer (BC) who responded to paclitaxel+bevacizumab.

Major finding: After a median follow-up of 21.3 months, the time to failure of the  strategy was longer with ET+bevacizumab vs weekly paclitaxel+bevacizumab among all induction chemotherapy responders (hazard ratio 0.51; log-rank P = .0006). The incidence of grade 3-5 adverse events was 10% lower in the ET+bevacizumab group.

Study details: Findings are from the phase 2, BOOSTER trial including 160 chemotherapy naive patients with ER+/HER2− advanced/metastatic BC who responded to weekly paclitaxel+bevacizumab induction, and were randomly assigned to continue paclitaxel+bevacizumab or switch to ET+bevacizumab.

Disclosures: This study was funded by Chugai Pharmaceutical. Some authors declared contracting clinical trials, serving as board members, or receiving institutional grants, honoraria, or personal fees from several sources.

Source: Saji S et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): A randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23(5):636-649 (Apr 8). Doi: 10.1016/S1470-2045(22)00196-6

Key clinical point: Switch to maintenance endocrine therapy (ET)+bevacizumab with an option of reinduction may be a better alternative to continuing weekly paclitaxel+bevacizumab in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced/metastatic breast cancer (BC) who responded to paclitaxel+bevacizumab.

Major finding: After a median follow-up of 21.3 months, the time to failure of the  strategy was longer with ET+bevacizumab vs weekly paclitaxel+bevacizumab among all induction chemotherapy responders (hazard ratio 0.51; log-rank P = .0006). The incidence of grade 3-5 adverse events was 10% lower in the ET+bevacizumab group.

Study details: Findings are from the phase 2, BOOSTER trial including 160 chemotherapy naive patients with ER+/HER2− advanced/metastatic BC who responded to weekly paclitaxel+bevacizumab induction, and were randomly assigned to continue paclitaxel+bevacizumab or switch to ET+bevacizumab.

Disclosures: This study was funded by Chugai Pharmaceutical. Some authors declared contracting clinical trials, serving as board members, or receiving institutional grants, honoraria, or personal fees from several sources.

Source: Saji S et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): A randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23(5):636-649 (Apr 8). Doi: 10.1016/S1470-2045(22)00196-6

Key clinical point: Switch to maintenance endocrine therapy (ET)+bevacizumab with an option of reinduction may be a better alternative to continuing weekly paclitaxel+bevacizumab in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced/metastatic breast cancer (BC) who responded to paclitaxel+bevacizumab.

Major finding: After a median follow-up of 21.3 months, the time to failure of the  strategy was longer with ET+bevacizumab vs weekly paclitaxel+bevacizumab among all induction chemotherapy responders (hazard ratio 0.51; log-rank P = .0006). The incidence of grade 3-5 adverse events was 10% lower in the ET+bevacizumab group.

Study details: Findings are from the phase 2, BOOSTER trial including 160 chemotherapy naive patients with ER+/HER2− advanced/metastatic BC who responded to weekly paclitaxel+bevacizumab induction, and were randomly assigned to continue paclitaxel+bevacizumab or switch to ET+bevacizumab.

Disclosures: This study was funded by Chugai Pharmaceutical. Some authors declared contracting clinical trials, serving as board members, or receiving institutional grants, honoraria, or personal fees from several sources.

Source: Saji S et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): A randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23(5):636-649 (Apr 8). Doi: 10.1016/S1470-2045(22)00196-6

Key clinical point: Atopic dermatitis (AD) had a detrimental impact on the families of pediatric patients, with not only severe AD but even mild AD having a substantial impact on family life.

Major finding: There was a substantial impact of AD on families across geographic regions, as assessed by Dermatitis Family Impact (DFI) score, which increased with the severity of AD (mild: 3.3-11.3, moderate: 6.9-17.1, and severe: 11-20.3). A DFI score of >9.6 was reported for 37.2%, 70.7%, and 78.0% of patients with mild, moderate, and severe AD, respectively.

Study details: Findings are from the cross-sectional, web-based survey including 7465 pairs of pediatric patients with AD and their parents/caregivers.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Five authors declared being current or former employees or stockholders of Sanofi or Regeneron Pharmaceuticals, and some others declared ties with various sources.

Source: Barbarot S et al. The family impact of atopic dermatitis in the pediatric population: Results from an international cross-sectional study. J Pediatr. 2022 (Apr 28). Doi: 10.1016/j.jpeds.2022.04.027

Key clinical point: Atopic dermatitis (AD) had a detrimental impact on the families of pediatric patients, with not only severe AD but even mild AD having a substantial impact on family life.

Major finding: There was a substantial impact of AD on families across geographic regions, as assessed by Dermatitis Family Impact (DFI) score, which increased with the severity of AD (mild: 3.3-11.3, moderate: 6.9-17.1, and severe: 11-20.3). A DFI score of >9.6 was reported for 37.2%, 70.7%, and 78.0% of patients with mild, moderate, and severe AD, respectively.

Study details: Findings are from the cross-sectional, web-based survey including 7465 pairs of pediatric patients with AD and their parents/caregivers.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Five authors declared being current or former employees or stockholders of Sanofi or Regeneron Pharmaceuticals, and some others declared ties with various sources.

Source: Barbarot S et al. The family impact of atopic dermatitis in the pediatric population: Results from an international cross-sectional study. J Pediatr. 2022 (Apr 28). Doi: 10.1016/j.jpeds.2022.04.027

Key clinical point: Atopic dermatitis (AD) had a detrimental impact on the families of pediatric patients, with not only severe AD but even mild AD having a substantial impact on family life.

Major finding: There was a substantial impact of AD on families across geographic regions, as assessed by Dermatitis Family Impact (DFI) score, which increased with the severity of AD (mild: 3.3-11.3, moderate: 6.9-17.1, and severe: 11-20.3). A DFI score of >9.6 was reported for 37.2%, 70.7%, and 78.0% of patients with mild, moderate, and severe AD, respectively.

Study details: Findings are from the cross-sectional, web-based survey including 7465 pairs of pediatric patients with AD and their parents/caregivers.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Five authors declared being current or former employees or stockholders of Sanofi or Regeneron Pharmaceuticals, and some others declared ties with various sources.

Source: Barbarot S et al. The family impact of atopic dermatitis in the pediatric population: Results from an international cross-sectional study. J Pediatr. 2022 (Apr 28). Doi: 10.1016/j.jpeds.2022.04.027

Key clinical point: Children diagnosed with atopic dermatitis (AD) within the first 10 years of life are more likely to develop a more proinflammatory dietary pattern and consume less fiber and several vitamins, which may worsen the atopic outcome itself.

Major finding: The intake of fiber (P = .04), vitamin C (P = .02), vitamin E (P = .03), and vitamin B₇ (biotin) (P = .047) were significantly lower among children who developed vs did not develop AD in the first 10 years of life, with a significant association observed between presence of AD and a proinflammatory dietary pattern at 10 years of age (odds ratio 2.22; P = .02).

Study details: Findings are from the population-based LiNA cohort study including 211 10-year-old children.

Disclosures: This LiNA study was funded by the Department of Environmental Immunology, Helmholtz Centre for Environmental Research. JR Hebert declared owning controlling interest in Connecting Health Innovations LLC.

Source: Schütte O et al. Pro-inflammatory diet pictured in children with atopic dermatitis or food allergy: Nutritional data of the LiNA cohort. Front Nutr. 2022;9:868872 (Apr 8). Doi: 10.3389/fnut.2022.868872

Key clinical point: Children diagnosed with atopic dermatitis (AD) within the first 10 years of life are more likely to develop a more proinflammatory dietary pattern and consume less fiber and several vitamins, which may worsen the atopic outcome itself.

Major finding: The intake of fiber (P = .04), vitamin C (P = .02), vitamin E (P = .03), and vitamin B₇ (biotin) (P = .047) were significantly lower among children who developed vs did not develop AD in the first 10 years of life, with a significant association observed between presence of AD and a proinflammatory dietary pattern at 10 years of age (odds ratio 2.22; P = .02).

Study details: Findings are from the population-based LiNA cohort study including 211 10-year-old children.

Disclosures: This LiNA study was funded by the Department of Environmental Immunology, Helmholtz Centre for Environmental Research. JR Hebert declared owning controlling interest in Connecting Health Innovations LLC.

Source: Schütte O et al. Pro-inflammatory diet pictured in children with atopic dermatitis or food allergy: Nutritional data of the LiNA cohort. Front Nutr. 2022;9:868872 (Apr 8). Doi: 10.3389/fnut.2022.868872

Key clinical point: Children diagnosed with atopic dermatitis (AD) within the first 10 years of life are more likely to develop a more proinflammatory dietary pattern and consume less fiber and several vitamins, which may worsen the atopic outcome itself.

Major finding: The intake of fiber (P = .04), vitamin C (P = .02), vitamin E (P = .03), and vitamin B₇ (biotin) (P = .047) were significantly lower among children who developed vs did not develop AD in the first 10 years of life, with a significant association observed between presence of AD and a proinflammatory dietary pattern at 10 years of age (odds ratio 2.22; P = .02).

Study details: Findings are from the population-based LiNA cohort study including 211 10-year-old children.

Disclosures: This LiNA study was funded by the Department of Environmental Immunology, Helmholtz Centre for Environmental Research. JR Hebert declared owning controlling interest in Connecting Health Innovations LLC.

Source: Schütte O et al. Pro-inflammatory diet pictured in children with atopic dermatitis or food allergy: Nutritional data of the LiNA cohort. Front Nutr. 2022;9:868872 (Apr 8). Doi: 10.3389/fnut.2022.868872

Key clinical point: Antioxidants show favorable efficacy and safety as an adjunct therapy for atopic dermatitis (AD), particularly when supplemented with oral vitamin D and topical vitamin B₁₂.

Major finding: Overall, antioxidants vs placebo were associated with a significant reduction in disease severity scores (P < .0001), with a significant decrease in AD severity observed for oral supplementation with vitamin D (P = .01); combined vitamins D and E (P = .003); combined vitamins A, D, and E (P = .02); and topical vitamin B₁₂ (P < .0001). No serious adverse events were reported.

Study details: Findings are from a meta-analysis of 18 studies including 763 patients with AD.

Disclosures: This study did not receive any funding. No conflict of interests was reported.

Source: Yang H et al. Efficacy and safety profile of antioxidants in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Dermatol Ther. 2022 (May 3). Doi: 10.1111/dth.15549

Key clinical point: Antioxidants show favorable efficacy and safety as an adjunct therapy for atopic dermatitis (AD), particularly when supplemented with oral vitamin D and topical vitamin B₁₂.

Major finding: Overall, antioxidants vs placebo were associated with a significant reduction in disease severity scores (P < .0001), with a significant decrease in AD severity observed for oral supplementation with vitamin D (P = .01); combined vitamins D and E (P = .003); combined vitamins A, D, and E (P = .02); and topical vitamin B₁₂ (P < .0001). No serious adverse events were reported.

Study details: Findings are from a meta-analysis of 18 studies including 763 patients with AD.

Disclosures: This study did not receive any funding. No conflict of interests was reported.

Source: Yang H et al. Efficacy and safety profile of antioxidants in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Dermatol Ther. 2022 (May 3). Doi: 10.1111/dth.15549

Key clinical point: Antioxidants show favorable efficacy and safety as an adjunct therapy for atopic dermatitis (AD), particularly when supplemented with oral vitamin D and topical vitamin B₁₂.

Major finding: Overall, antioxidants vs placebo were associated with a significant reduction in disease severity scores (P < .0001), with a significant decrease in AD severity observed for oral supplementation with vitamin D (P = .01); combined vitamins D and E (P = .003); combined vitamins A, D, and E (P = .02); and topical vitamin B₁₂ (P < .0001). No serious adverse events were reported.

Study details: Findings are from a meta-analysis of 18 studies including 763 patients with AD.

Disclosures: This study did not receive any funding. No conflict of interests was reported.

Source: Yang H et al. Efficacy and safety profile of antioxidants in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Dermatol Ther. 2022 (May 3). Doi: 10.1111/dth.15549

Key clinical point: Dupilumab improved clinical scores in a real-world population of adolescents with moderate-to-severe atopic dermatitis (AD) and had a tolerable safety profile.

Major finding: After 16 weeks, the mean Eczema Area and Severity Index (EASI) score and Children Dermatology Life Quality Index and Numeric Rating Scale sleep loss scores reduced significantly by 79.8%, 72.9%, and 75.8%, respectively (all P < .01), with a higher proportion of patients with diffuse eczema vs. other clinical phenotypes reporting ≥90% and 100% improvement in EASI scores (P < .05). Adverse events (AE) were reported by 20.1% of adolescents, but none discontinued dupilumab because of AE.

Study details: This prospective study included 139 adolescents aged ≥12 to <18 years with moderate-to-severe AD who received dupilumab for 16 weeks.

Disclosures: This study did not receive any funding. Some authors declared serving as principal investigators, advisory board members, speakers, or consultants, or receiving personal fees, consulting fees, or payments or honoraria from several sources.

Source: Stingeni L et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022 (Apr 12). Doi: 10.1111/jdv.18141

Key clinical point: Dupilumab improved clinical scores in a real-world population of adolescents with moderate-to-severe atopic dermatitis (AD) and had a tolerable safety profile.

Major finding: After 16 weeks, the mean Eczema Area and Severity Index (EASI) score and Children Dermatology Life Quality Index and Numeric Rating Scale sleep loss scores reduced significantly by 79.8%, 72.9%, and 75.8%, respectively (all P < .01), with a higher proportion of patients with diffuse eczema vs. other clinical phenotypes reporting ≥90% and 100% improvement in EASI scores (P < .05). Adverse events (AE) were reported by 20.1% of adolescents, but none discontinued dupilumab because of AE.

Study details: This prospective study included 139 adolescents aged ≥12 to <18 years with moderate-to-severe AD who received dupilumab for 16 weeks.

Disclosures: This study did not receive any funding. Some authors declared serving as principal investigators, advisory board members, speakers, or consultants, or receiving personal fees, consulting fees, or payments or honoraria from several sources.

Source: Stingeni L et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022 (Apr 12). Doi: 10.1111/jdv.18141

Key clinical point: Dupilumab improved clinical scores in a real-world population of adolescents with moderate-to-severe atopic dermatitis (AD) and had a tolerable safety profile.

Major finding: After 16 weeks, the mean Eczema Area and Severity Index (EASI) score and Children Dermatology Life Quality Index and Numeric Rating Scale sleep loss scores reduced significantly by 79.8%, 72.9%, and 75.8%, respectively (all P < .01), with a higher proportion of patients with diffuse eczema vs. other clinical phenotypes reporting ≥90% and 100% improvement in EASI scores (P < .05). Adverse events (AE) were reported by 20.1% of adolescents, but none discontinued dupilumab because of AE.

Study details: This prospective study included 139 adolescents aged ≥12 to <18 years with moderate-to-severe AD who received dupilumab for 16 weeks.

Disclosures: This study did not receive any funding. Some authors declared serving as principal investigators, advisory board members, speakers, or consultants, or receiving personal fees, consulting fees, or payments or honoraria from several sources.

Source: Stingeni L et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022 (Apr 12). Doi: 10.1111/jdv.18141